Norman Law
About Norman Law
Norman Law serves as the Head of Intellectual Property at Adaptimmune and has extensive experience in the biotechnology and pharmaceutical industries, particularly in rare diseases. He holds a BSc Hons in Biochemistry from The University of Edinburgh and a PhD from the University of Leeds, along with various research fellowships.
Current Role at Adaptimmune
Norman Law serves as the Head of Intellectual Property at Adaptimmune, a position he has held since 2016. In this role, he oversees the management and strategy of intellectual property within the organization. His work focuses on supporting the company's objectives in the biotechnology sector, particularly in the development of therapies for rare diseases. Adaptimmune is based in Oxford, United Kingdom, where Law continues to contribute to the advancement of innovative treatments.
Previous Experience at Novartis
Prior to his current role, Norman Law worked at Novartis as a Biochemist from 1993 to 1997. His tenure at Novartis took place in the Basel Area of Switzerland, where he engaged in biochemical research and development. This experience provided him with a strong foundation in the pharmaceutical industry, which he has built upon throughout his career.
Educational Background
Norman Law has an extensive educational background in the life sciences. He earned a Bachelor of Science with Honours in Biochemistry from The University of Edinburgh. He furthered his studies at Cornell University, where he obtained a Certificate in Financial Management. Law also completed a PhD in Biochemistry at the University of Leeds. His research training includes a Research Fellowship in Cell Biology and Ophthalmology at Yale University School of Medicine and a Research Fellowship in Pharmacology at the Medical University of South Carolina.
Experience in Intellectual Property Management
Law has significant experience in intellectual property management within the biotechnology sector. He served as the Director of Intellectual Property at Onxeo, formerly known as TopoTarget A/S, from 2002 to 2014 in Copenhagen, Denmark. Additionally, he worked as the Manager of Commercial Analysis and IP at Adaptimmune from 2013 to 2016. His expertise includes technology evaluation and competitive intelligence, which are critical for navigating the complexities of the biotech industry.
Co-Founder Role at MitoRx Therapeutics
In 2021, Norman Law co-founded MitoRx Therapeutics, where he currently serves as Director. This role allows him to leverage his extensive background in biochemistry and intellectual property to advance the development of mitochondrial sulfide donor small molecule drugs. His focus is on activating endogenous mitochondrial protection pathways, contributing to innovative solutions in the biotechnology field.